Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy
June 12, 2015 7:30 AM EDTNeedham & Company reiterates a Buy rating and $22.00 price target on Summit Therapeutics plc (NASDAQ: SMMT) as SMT C1100 pharmacokinetics and muscle biomarkers trial is now fully enrolled and dosing patients. topline data is expected in 3Q15.
Analyst Chad Messer commented, "Summit... More
